MSD (China) Investment Co., Ltd.

MSD (China) Investment Co., Ltd. is a company in Shanghai, China. Its official site describes MSD as a research-intensive biopharmaceutical company working to develop and provide innovative medicines, vaccines and animal health products, with the goal of harnessing frontier science to save and improve lives globally. The company states it has been developing important medicines and vaccines for more than 130 years, and lists business areas including oncology, vaccines, anti-infectives, and cardiovascular and metabolic diseases.

MSD (China) Investment Co., Ltd. is the China investment and operating company of MSD, the brand under which Merck & Co., Inc. conducts business outside the United States and Canada. The parent organization traces its roots to the late 19th century and states that it has been developing important medicines and vaccines for more than 130 years. Over that period, Merck & Co. grew into a global research-intensive biopharmaceutical company with a broad portfolio spanning human health and animal health. The Chinese entity is registered in Shanghai and serves as the group's investment holding and commercial platform in China. Its official website presents the company's vision of changing lives worldwide through innovative medicines, vaccines and animal health products, and its goal of being a leading research-intensive biopharmaceutical company. The site also outlines the company's core values — patients first, respect for people, ethics and integrity, and innovation and scientific excellence — which it says guide every decision and action. In China, the company's business is organized around several therapeutic and preventive areas: oncology, vaccines, anti-infectives (including HIV and Ebola), and cardiovascular and metabolic diseases such as cardiovascular disease and diabetes. The corporate profile highlights patient care, research and corporate social responsibility as central pillars of its local presence, and it cites global figures for the wider MSD group, including 92% product reach, US$17.9 billion in annual research and development spending, and US$64.2 billion in annual sales. As a subsidiary of Merck & Co., Inc., which is publicly listed in the United States under the ticker MRK, MSD (China) Investment Co., Ltd. operates within the governance and reporting framework of its parent. The Chinese entity's activities are closely tied to the parent's global mission of using leading-edge science to save and improve lives, and to improving access to medicines and vaccines in China.

Research-intensive biopharmaceutical company focused on innovative medicines, vaccines and animal health products.

• Oncology

  Mission to discover, develop and provide innovations that can extend the lives of cancer patients and improve their quality of life.

• Vaccines

  Vaccines described as one of the most effective areas of public health, with a century of exploration, development and delivery of disease-prevention vaccines.

• Anti-infectives

  Exploration and development of innovative medicines and vaccines for treating and preventing infectious diseases, including HIV and Ebola.

• Cardiovascular and metabolic diseases

  Efforts to find solutions for serious chronic diseases such as cardiovascular disease and diabetes.

1. 1默沙东（中国）投资有限公司官网msdchina.com.cn
2. 2公司概况 - 默沙东（中国）投资有限公司官网msdchina.com.cn
3. 3MSD (China) Investment Co., Ltd. (China) - Wikidatawikidata.org